METHODS
rhinoconjunctivitis, mild/moderate asthma, asthma
RHINOCONJUNCTIVITIS, DISEASE, SECONDARY, ASTHMA, TSS
We present data from an observational, single‐center study conducted at Hospital Universitario Ntra. Sra. de La Candelaria (Santa Cruz de Tenerife, Spain) for a 10‐year follow‐up (10y‐FU) of adult patients, who initially participated in a double‐blind placebo‐controlled clinical trial (DBPCT) and received subcutaneous immunotherapy (SCIT) treatment with a depigmented, polymerized house dust mite (dpg‐pol HDM) allergen extract or placebo during a 54 week period. Data from those patients who agreed to continue with dpg‐pol HDM SCIT (following real‐life routine clinical practice) for a further period after the completion of the DBPCT, were the objective of this study and the results are presented in this article (Figure Study design.The initial DBPCT included patients diagnosed with mild/moderate asthma with/without rhinoconjunctivitis due to HDM. Patients (Once the DBPCT was completed, patients from both groups were invited to receive dpg‐pol HDM under routine clinical practice. This observational retrospective study was designed to assess the long‐term effectiveness for AR and asthma of dpg‐pol HDM in a 10y‐FU visit. Changes in the Total Symptom Score (TSS) and Medication Score (MS) were the primary objectives. Visual analog scale (VAS), asthma control test (ACT), and the degree of disease control assessed by the physician were the secondary objectives. Data were analyzed at three different time‐points: baseline (before dpg‐pol HDM), end of dpg‐pol HDM SCIT, and 10y‐FU visit (Figure 